Based on strengths in glycobiology, microbial biotechnology, biological system’s engineering and bio-analytics, our research group is developing innovative molecular technology to enable novel approaches to study, diagnose and treat immune-system related disease.

We exploit the developed technologies for our own research interests in inflammation and immunity, in collaboration with experts within and outside of CMB. For development and exploitation of our technologies in other fields, we collaborate intensively with the biotechnology and pharmaceutical industry. At the moment, our strategic technology development focuses on microbial cell engineering as a basis for the discovery and development of novel immunomodulatory biopharmaceuticals. We are also developing new glyco-analysis tools and animal models to pursue the role of inflammation-induced lymphocyte glycosylation changes in the pathophysiology of inflammatory disease.